Novel Agents in the
Treatment of Lung Cancer

New Approaches to First-Line Therapies

CME Information

Up to 3 AMA PRA Category 1 Credit(s)™

Release date: January 2010        Valid through: January 2011

Course Material: Online Only

Receiving CME Credit

To receive online CME credit for this activity, read the full activity then click below to complete the post-test and evaluation hosted on freeCME.com. You will be able to print your CME certificate immediately following completion of the post-test and evaluation.

CME Test and Evaluation

Target Audience
This educational activity is intended for oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.

Educational Objectives
After completing this activity, participants should be able to:

• Discuss considerations in assessing patients presenting with advanced NSCLC.
• Discuss considerations in determining first-line treatment options for patients presenting with advanced NSCLC.
• Discuss considerations in integrating supportive care and managing brain metastasis in treatment strategies for patients with advanced NSCLC.
• Implement appropriate treatment and supportive care strategies into practice in assessing, counseling and treating patients with advanced NSCLC.

Educational Need
Results of important recent clinical studies of first-line EGFR TKI therapies, antibodies combined with chemotherapy, consolidation and up-front supportive care are creating the potential to change the paradigm for what constitutes appropriate first-line care for non–small cell lung cancer (NSCLC) patients. Medical professionals who work with lung cancer patients need to understand the results of these new studies assess their implications for the management of NSCLC and integrate this information into their practice of assessing, counseling and treating individual patients.

Companion CME Activity
A companion CME activity, Lung Cancer: Case Studies Assessing Novel Agents in First-Line Therapy, based on videotaped discussion of cases is available at First-Line Case Studies. The activity provides more in-depth information on this topic, featuring an overview by Thomas J. Lynch, Jr, MD, and discussion of 4 cases by the same program faculty that developed this activity. The activity offers up to 2 additional AMA PRA Category 1 Credits™.

Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.

Educational Grant Support
The program is supported by educational grants provided by Bristol-Myers Squibb and ImClone Systems Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.

Credit Designation
InforMEDical designates this continuing medical education activity for up to 2 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

NEXT > >